Novo Nordisk and Sanofi on Tuesday laid out their cases for the next phase of the legal battle over their conditions on 340B pricing when covered entities use contract pharmacies.
Novo Nordisk and Sanofi on Tuesday laid out their cases for the next phase of the legal battle over their conditions on 340B pricing when covered entities use contract pharmacies.
*Sign up for news summaries and alerts from 340B Report